Zinc sulfate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for zinc sulfate and what is the scope of freedom to operate?
Zinc sulfate
is the generic ingredient in one branded drug marketed by Abraxis Pharm, Am Regent, Apotex, Fresenius Kabi Usa, Gland Pharma Ltd, Nivagen Pharms Inc, Somerset Theraps Llc, and Zydus Pharms, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for zinc sulfate. Nine suppliers are listed for this compound.
Summary for zinc sulfate
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 8 |
NDAs: | 8 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 48 |
Clinical Trials: | 1,080 |
Patent Applications: | 3,727 |
Drug Sales Revenues: | Drug sales revenues for zinc sulfate |
What excipients (inactive ingredients) are in zinc sulfate? | zinc sulfate excipients list |
DailyMed Link: | zinc sulfate at DailyMed |
Recent Clinical Trials for zinc sulfate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bellicum Pharmaceuticals | Phase 1/Phase 2 |
UNC Lineberger Comprehensive Cancer Center | Phase 1/Phase 2 |
University Cancer Research Fund at Lineberger Comprehensive Cancer Center | Phase 1/Phase 2 |
Pharmacology for zinc sulfate
Drug Class | Copper Absorption Inhibitor |
Physiological Effect | Decreased Copper Ion Absorption |
Medical Subject Heading (MeSH) Categories for zinc sulfate
Anatomical Therapeutic Chemical (ATC) Classes for zinc sulfate
US Patents and Regulatory Information for zinc sulfate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nivagen Pharms Inc | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 214597-003 | Jul 5, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Nivagen Pharms Inc | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 214597-002 | Jul 5, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Am Regent | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 209377-001 | Jul 18, 2019 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Nivagen Pharms Inc | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 214597-001 | Jul 5, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Zinc sulfate Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.